explored the effects of EcN engineered to produce EGF (EGF‐EcN) in a mouse model of colitis‐associated cancer (CAC).[64] Remarkably, EGF‐EcN administration led to a significant reduction in both the number and size of tumors, curbed cell proliferation within the tumor mass, and diminished high‐grade dysplasia in the mucosa. Here, EGF is linked to neoplasm.